BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25130287)

  • 1. Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.
    Roug AS; Hansen MC; Nederby L; Hokland P
    Br J Haematol; 2014 Oct; 167(2):162-76. PubMed ID: 25130287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
    Marani C; Clavio M; Grasso R; Colombo N; Guolo F; Kunkl A; Ballerini F; Giannoni L; Ghiggi C; Fugazza G; Ravetti JL; Gobbi M; Miglino M
    Leuk Res; 2013 Dec; 37(12):1606-11. PubMed ID: 23891447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
    Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
    Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution.
    Hirsch P; Labopin M; Viguié F; Perot C; Isnard F; Mamez AC; Bilhou-Nabera C; Marzac C; Delhommeau F; Lapusan S; Marie JP; Mohty M; Legrand O
    Leuk Res; 2014 Aug; 38(8):907-12. PubMed ID: 24957411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.
    Ossenkoppele GJ; van de Loosdrecht AA; Schuurhuis GJ
    Br J Haematol; 2011 May; 153(4):421-36. PubMed ID: 21385170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.
    Hokland P; Ommen HB; Nyvold CG; Roug AS
    Br J Haematol; 2012 Sep; 158(5):569-80. PubMed ID: 22738609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.
    Liersch R; Müller-Tidow C; Berdel WE; Krug U
    Br J Haematol; 2014 Apr; 165(1):17-38. PubMed ID: 24484469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.
    Ghanem H; Tank N; Tabbara IA
    Am J Hematol; 2012 Jan; 87(1):69-77. PubMed ID: 22072438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of multiparameter flow cytometry for disease monitoring in AML.
    Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
    Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia.
    Derolf AR; Laane E; Björklund E; Saft L; Björkholm M; Porwit A
    Scand J Immunol; 2014 Dec; 80(6):424-31. PubMed ID: 25346147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group.
    Kinoshita A; Miyachi H; Matsushita H; Yabe M; Taki T; Watanabe T; Saito AM; Tomizawa D; Taga T; Takahashi H; Matsuo H; Kodama K; Ohki K; Hayashi Y; Tawa A; Horibe K; Adachi S
    Br J Haematol; 2014 Oct; 167(1):80-6. PubMed ID: 25039450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia.
    Tallman M
    J Natl Compr Canc Netw; 2018 May; 16(5S):656-659. PubMed ID: 29784749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.
    Jorgensen JL; Chen SS
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S49-53. PubMed ID: 22035748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.